Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are evaluating treatment options for younger patients with intermediate risk acute myeloid leukemia AML in this phase II trial. The study compares three different drug combinations cytarabine with daunorubicin cytarabine with daunorubicin plus venetoclax and venetoclax with azacitidine. The goal is to see if adding venetoclax improves the elimination of leukemia cells compared to the usual treatment, by measuring undetectable residual disease after therapy. Participants are randomly assigned to one of three treatment groups. One group receives daunorubicin and cytarabine with venetoclax over 28-day cycles, possibly followed by reinduction therapy based on bone marrow assessments. The second group receives azacitidine combined with venetoclax for two 28-day cycles. The third group receives daunorubicin and cytarabine alone, with potential reinduction treatment. Patients undergo bone marrow aspiration, blood sample collection, and heart function tests before and during the study. During the trial, participants will have regular evaluations including bone marrow tests and blood draws to monitor treatment effects and disease status. Heart function is assessed at screening with echocardiography or a MUGA scan. After completing treatment, patients are followed with visits at 4 weeks, every 3 months for the first year, every 6 months in the second year, and yearly thereafter. Researchers track remission rates, toxicities, survival outcomes, and responses based on genetic features for up to 10 years.
Actively Recruiting
Healthy Volunteer
This trial is studying advanced practice providers APPs who work in cancer care but may not regularly participate in clinical research at community oncology sites. It evaluates whether a mentorship and education program called COACH-APP can improve APPs confidence in their ability to engage in clinical research, known as research self-efficacy. The study aims to see if this program helps APPs integrate more meaningfully into research teams and potentially improves patient care and access to clinical trials. Participants are divided into groups where one receives the COACH-APP intervention, which includes completing a 6-module clinical research workshop over 2 hours, receiving a clinical trials research manual, and participating in five mentoring sessions lasting 15-60 minutes over 12 months. The comparison group receives only access to the workshop and manual for 12 months. Additionally, mentors providing the COACH-APP mentorship and selected research care team members participate in qualitative interviews to assess the interventions impact. During the study, participants complete surveys and interviews to measure changes in research self-efficacy, engagement with the National Cancer Institutes community oncology research program, integration into research care teams, and practice-level study activity over 12 to 24 months. The trial also evaluates the feasibility, acceptability, and appropriateness of the COACH-APP program. Participation involves training sessions, mentoring, surveys, and interviews over a 12-month period with follow-up assessments extending up to 24 months.
Actively Recruiting
Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.
Actively Recruiting
Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.
Actively Recruiting
Researchers are evaluating a Master Screening and Reassessment Protocol MSRP to improve the matching of patients with myeloid cancers, such as acute myeloid leukemia AML or myelodysplastic syndrome MDS, to appropriate clinical trials or standard treatments. This study focuses on using bone marrow and blood tests to detect biomarkers that guide treatment decisions, aiming to assign participants quickly to targeted treatment studies or standard care pathways. The study also assesses the ability to organize and process data rapidly to support treatment assignments. Participants undergo bone marrow aspiration and blood collection for rapid genetic testing to identify mutations that may be targeted by specific therapies within various substudies. If no targetable mutation is found, participants may be assigned to novel combination drug studies or continue standard of care through the Tier Advancement Pathway TAP. Treatments studied include various drug regimens involving agents such as azacitidine, venetoclax, cytarabine, daunorubicin, and others, administered intravenously, subcutaneously, or orally according to specific schedules. Some participants may also receive hematopoietic stem cell transplantation with conditioning regimens. Treatment cycles vary in length and number depending on the assigned substudy. Throughout the study, participants have multiple bone marrow aspirations, biopsies, blood sample collections, and imaging tests such as echocardiography or MUGA scans for monitoring. Researchers assess timing for treatment assignment, response rates, adverse events, and overall survival among other outcomes. The study includes ongoing reassessment to allow movement to higher tier treatment options when appropriate. Participation may last for extended periods, with some regimens continuing up to two years or more, depending on response and disease progression.
Actively Recruiting
Researchers are studying the relationship between low muscle mass myopenia at the time of diagnosis and chemotherapy side effects in older adults newly diagnosed with advanced colorectal cancer. This observational study focuses on patients receiving 5-Fluorouracil 5-FU based chemotherapy, including combinations with oxaliplatin, irinotecan, or immunotherapy. The study also investigates how genetic differences may influence the link between myopenia and chemotherapy toxicity. Participants include older adults with newly diagnosed metastatic colorectal cancer or recent metastatic recurrence who are starting or planning to start first-line immunotherapy andor 5-FU chemotherapy. The study examines chemotherapy toxicities graded 3 to 5 during the first 6 months after beginning treatment and tracks overall survival for one year. No specific treatments are administered by the study, as it observes patients undergoing standard care. During the study, participants chemotherapy side effects are monitored and recorded, along with survival outcomes. Questionnaires are used to gather patient information, and eligibility requires the ability to understand English or Spanish. The study collects data for up to one year to evaluate how muscle mass and genetics affect chemotherapy outcomes in this population.
Actively Recruiting
Healthy Volunteer
Researchers are studying how surgeons and surgical advanced practice providers APPs within the NCI Community Oncology Research Program NCORP use extended venous thromboembolism prophylaxis ePPx after abdominopelvic cancer surgery. The study aims to understand self-reported use of guideline-based ePPx, identify factors affecting its use, and explore barriers and supports for prescribing ePPx. This observational study is conducted within a network of cancer surgery providers to gather real-world insights. The study is divided into three parts Part 1 involves surgeons and APPs completing surveys about their use of ePPx after cancer surgery. Part 2 includes semi-structured interviews with a subset of these providers to discuss challenges and acceptability of clinical decision tools for VTE prophylaxis. Part 3 focuses on extracting electronic health record EHR data from select sites to evaluate the feasibility of identifying patients who had cancer surgery and received guideline-based ePPx. Participants will complete surveys and some will take part in interviews. Site contacts or research leads will also complete surveys and facilitate EHR data extraction. Researchers will measure how often guideline-consistent ePPx is reported and explore factors influencing its use, barriers, and feasibility of data collection. The study lasts at least one year from the start of the first part, with follow-up on interviews and EHR data extraction occurring within six months after each respective part begins.
Actively Recruiting
Researchers are evaluating various treatment regimens for patients aged 18 to 59 with high-risk acute myeloid leukemia AML, a form of blood cancer that is harder to treat. This Phase II trial compares the standard chemotherapy combination of cytarabine and daunorubicin against newer experimental therapies including daunorubicin and cytarabine liposome alone, combinations with venetoclax, and azacitidine with venetoclax. The study aims to assess which regimen can better eliminate measurable residual disease and improve remission rates. Participants are randomly assigned to one of five treatment groups. Treatments involve cycles of chemotherapy drugs administered intravenously or subcutaneously, combined with oral venetoclax in some arms. Each cycle lasts 28 days, with the possibility of additional cycles if there is no disease progression or unacceptable toxicity. Before starting treatment, participants undergo heart function tests ECHO or MUGA scans. Blood and bone marrow samples are collected throughout the trial to monitor disease status and response to therapy. During the study, participants receive scheduled treatments and regular assessments including bone marrow aspirations and blood draws. After completing treatment, follow-up visits occur monthly during the first year, every two months in the second year, every three months in the third year, and every six months up to five years. Researchers will measure outcomes such as remission rates, survival, relapse, and treatment side effects. Specimens are also collected for future research to better understand AML and treatment effects.
Actively Recruiting
Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.
1-10 of 11
1